At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 120 enrolled
Drug / intervention
Letermovirdrug
Likely dose
Letermovir 240 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Open Label, Single-Arm Clinical Trial to Evaluate the Efficacy and Safety of MK-8228 (Letermovir) for the Prevention of Clinically Significant Cytomegalovirus (CMV) Infection in Chinese Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients
In Brief
A Phase 3 clinical trial evaluating Letermovir for Cytomegalovirus Infection. Completed, enrolled 120 participants across 21 sites.
Detailed Summary
The purpose of this study is to evaluate the efficacy and safety of a once-a-day oral or intravenous (IV) dose of Letermovir (MK-8228) in Chinese adult hematopoietic stem cell transplant (HSCT) recipients for the prevention of clinically significant cytomegalovirus (CMV) infection.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCytomegalovirus Infection
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
202420252026
First PostedMar 2023
Enrollment StartMar 2023
Primary CompletionApr 2024
TodayJul 2026
First PostedMar 10, 2023
Enrollment StartMar 24, 2023
Primary CompletionApr 18, 2024
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 3.3 years ago
Interventions
Letermovirdrug
Daily 240 mg or 480 mg oral tablets or IV dose